share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  2024/12/05 05:33

Moomoo AI 已提取核心訊息

Cardio Diagnostics has received a second extension from Nasdaq until June 2, 2025, to regain compliance with the minimum bid price requirement of $1.00 per share. This follows the company's initial 180-day compliance period that began on June 3, 2024, which expired without achieving compliance.The extension was granted based on the company meeting all Nasdaq Capital Market initial listing requirements except the minimum bid price requirement. To maintain listing, Cardio Diagnostics must achieve a closing bid price of at least $1.00 for a minimum of 10 consecutive business days before the new deadline. The company is considering various options, including a potential reverse stock split.If compliance is not achieved by June 2, 2025, the company faces potential delisting, though it would have the right to appeal before the Nasdaq Hearings Panel. Currently, this notice has no immediate impact on the trading status of the company's common stock.
Cardio Diagnostics has received a second extension from Nasdaq until June 2, 2025, to regain compliance with the minimum bid price requirement of $1.00 per share. This follows the company's initial 180-day compliance period that began on June 3, 2024, which expired without achieving compliance.The extension was granted based on the company meeting all Nasdaq Capital Market initial listing requirements except the minimum bid price requirement. To maintain listing, Cardio Diagnostics must achieve a closing bid price of at least $1.00 for a minimum of 10 consecutive business days before the new deadline. The company is considering various options, including a potential reverse stock split.If compliance is not achieved by June 2, 2025, the company faces potential delisting, though it would have the right to appeal before the Nasdaq Hearings Panel. Currently, this notice has no immediate impact on the trading status of the company's common stock.
Cardio Diagnostics 已獲得納斯達克的第二次延期,截止日期爲 2025 年 6 月 2 日,以恢復符合每股 1.00 美元的最低買盤價格要求。這是公司在 2024 年 6 月 3 日開始的初始 180 天合規期到期後,沒有達到合規。這一延期是基於公司滿足所有納斯達克資本市場最初上市要求,唯獨最低買盤價格要求未能滿足。爲了維持上市,Cardio Diagnostics 必須在新的截止日期之前實現至少連續 10 個交易日的收盤買盤價格至少爲 1.00 美元。公司正在考慮多種期權,包括潛在的反向股票拆分。如果在 2025 年 6 月 2 日之前未能達到合規,公司面臨潛在的退市,儘管它有權在納斯達克聽證委員會之前提出上訴。目前,這個通知對公司的普通股交易狀態沒有立即影響。
Cardio Diagnostics 已獲得納斯達克的第二次延期,截止日期爲 2025 年 6 月 2 日,以恢復符合每股 1.00 美元的最低買盤價格要求。這是公司在 2024 年 6 月 3 日開始的初始 180 天合規期到期後,沒有達到合規。這一延期是基於公司滿足所有納斯達克資本市場最初上市要求,唯獨最低買盤價格要求未能滿足。爲了維持上市,Cardio Diagnostics 必須在新的截止日期之前實現至少連續 10 個交易日的收盤買盤價格至少爲 1.00 美元。公司正在考慮多種期權,包括潛在的反向股票拆分。如果在 2025 年 6 月 2 日之前未能達到合規,公司面臨潛在的退市,儘管它有權在納斯達克聽證委員會之前提出上訴。目前,這個通知對公司的普通股交易狀態沒有立即影響。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息